Thuja Capital
Investor profile
Deals
13
distinct rounds
Companies
11
backed
Active span
2014–2026
13 yrs
Total round €
€164M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- BioGeneration Ventures2
- Flerie Invest2
- INKEF Capital2
- 819 Capital1
- Ackermans & van Haaren1
- Asabys Partners1
- BNP Paribas Fortis Private Equity1
- Boehringer Ingelheim Venture Fund (BIVF)1
- Bolwork International Investment1
- Brabant Development Agency1
- Brabant Development Agency (BOM)1
- Casdin Capital1
- Chemelot Ventures1
- Creathor Venture1
- Dolby Family Ventures1
- dsm-firmenich Ventures1
- EIC Fund1
- Eurazeo1
- Flanders Future Techfund (FFTF)1
- FundPlus1
- Gilde Healthcare1
- Health Innovations1
- High-Tech Gründerfonds1
- High-Tech Gründerfonds (HTGF)1
- Index Ventures1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Salvia BioElectronics | Netherlands | 1 | €53M |
| AstriVax | Belgium | 1 | €30M |
| Gradient Denervation Technologies | France | 1 | €14M |
| NightBalance | Netherlands | 1 | €13M |
| Synerkine Pharma | Netherlands | 3 | €12M |
| tacalyx | Germany | 1 | €11M |
| FundaMental Pharma | Germany | 1 | €10M |
| InnoSIGN | Netherlands | 1 | €7.3M |
| Cristal Therapeutics | Netherlands | 1 | €6.0M |
| EnCare Biotech | Netherlands | 1 | €5.0M |
| ATRO Medical | Netherlands | 1 | €3.0M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Salvia BioElectronics | Series B | €53M | 2025-05 |
| AstriVax | Seed | €30M | 2022-08 |
| Gradient Denervation Technologies | Series A | €14M | 2023-09 |
| NightBalance | Series B | €13M | 2016-06 |
| tacalyx | Seed | €11M | 2026-04 |
| FundaMental Pharma | Seed | €10M | 2022-11 |
| InnoSIGN | Series A | €7.3M | 2022-04 |
| Cristal Therapeutics | Early VC | €6.0M | 2014-11 |
| Synerkine Pharma | Series A | €5.3M | 2023-10 |
| EnCare Biotech | Series A | €5.0M | 2014-10 |